


# Supplementary Materials

## I. PRISMA 2009 Flow Diagram:



## II. PICOS-T

Component	Description
Population (P)	Adult patients with metastatic triple-negative breast cancer (mTNBC)
Intervention (I)	Sacituzumab govitecan (SG)
Comparator (C)	Chemotherapy
Outcomes (O)	Life years (LYs) gained, quality-adjusted life-years (QALYs), incremental cost, incremental cost-effectiveness ratio (ICER), and incremental net monetary benefit (INMB)
Study Design (S)	Cost-effectiveness and cost-utility analyses
Time Period (T)	Studies published up to December 2025

## III. Bibliography

- [1] Wang L, Liu L, Zhang Z, Li F, Ruan Y, He Y, Huang J, Zheng X. Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for patients with metastatic triple-negative breast cancer in China. *Clin Breast Cancer*. 2024;24(7):e545–e553.e6. doi:10.1016/j.clbc.2024.04.010.
- [2] Wu Y, Hu S, Liu X, Chen Y, Luan J, Wang S. Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis. *Cost Eff Resour Alloc*. 2024;22(1):32. doi:10.1186/s12962-024-00539-y.
- [3] Xie J, Li S, Li Y, Li J. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer. *BMC Health Serv Res*. 2023;23(1):706. doi:10.1186/s12913-023-09728-6.
- [4] Lang Y, Chai Q, Tao W, Liao Y, Liu X, Wu B. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. *Breast*. 2023;68:173–180. doi:10.1016/j.breast.2023.02.003.
- [5] Chen J, Han M, Liu A, Shi B. Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in China and the US. *Front Oncol*. 2021;11:734594. doi:10.3389/fonc.2021.734594.
- [6] Liu S, Wang K, Wang R, Chen H, Wan Z, Dou L, Li S. Cost-effectiveness of antibody-drug conjugates in previously treated metastatic triple-negative breast cancer in China. *Health Econ Rev*. 2025;15(1):105. doi:10.1186/s13561-025-00700-0.
- [7] Fenix-Caballero S, Del Rey EJA, Špacírová Z, de Labry Lima AO. Cost-effectiveness of sacituzumab govitecan and physician's choice of treatment in patients with metastatic triple-negative breast cancer in Spain. *Clin Drug Investig*. 2025. doi:10.1007/s40261-025-01499-8.
- [8] Wang SY, Tai YS, Leung HWC, Leung SH, Chan ALF. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer in Taiwan. *Cancers (Basel)*. 2025;17(20):3305. doi:10.3390/cancers17203305.